SCHEMBL476492

SCHEMBL476492

CCNC(CC)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.46
TSHR P16473 2/20 0.46
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
HSD17B10 Q99714 1/20 0.46
SIGMAR1 Q99720 1/20 0.45
MTOR P42345 1/20 0.43
RAB9A P51151 1/20 0.43
GRM7 Q14831 1/20 0.43
EPHX2 P34913 2/20 0.41
NPC1 O15118 1/20 0.41
CYP3A4 P08684 2/20 0.41
ALOX15 P16050 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
ASPH Q12797 1/20 0.40
KDM8 Q8N371 1/20 0.40
KCNA5 P22460 1/20 0.40
TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13970878 1.00 LMNA (0.46) LMNATSHRKDM4EALDH1A1HPGD
SCHEMBL12228438 1.00 LMNA (0.46) LMNATSHRKDM4EALDH1A1HPGD
Hydrochloric Acid SCHEMBL20446671 0.98 LMNA (0.45) LMNATSHRKDM4EALDH1A1HPGD
SCHEMBL2847032 0.83 LMNA (0.52) LMNATSHRKDM4EALDH1A1HPGD
SCHEMBL13911223 0.83 SIGMAR1 (0.48) LMNATSHRKDM4EALDH1A1HPGD
SCHEMBL10282547 0.83 RIPK1 (0.51) LMNASIGMAR1MTORRAB9AGRM7
SCHEMBL11622496 0.83 TAAR1 (0.48) SIGMAR1MTORRAB9AGRM7
SCHEMBL13520315 0.83 RIPK1 (0.51) LMNASIGMAR1MTORRAB9AGRM7
SCHEMBL20817230 0.83 SIGMAR1 (0.47) LMNATSHRKDM4EALDH1A1HPGD
SCHEMBL13051383 0.83 HTT (0.49) LMNATSHRALDH1A1SIGMAR1MTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9982015-B2 Cyclin based inhibitors of CDK2 and CDK4 UNIVERSITY OF SOUTH CAROLINA (US) 2018-05-29 US claimed
US-20170218018-A1 CYCLIN BASED INHIBITORS OF CDK2 AND CDK4 NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-08-03 US claimed
US-20230159475-A1 COMPOUNDS WITH IMMUNOMODULATORY ACTIVITY AND THERAPEUTIC USES THEREOF PURDUE RESEARCH FOUNDATION (US) 2023-05-25 US disclosed
WO-2022058809-A1 MULTILAYER POLYMERIC MATRIX UNIVERSIDAD DE LOS ANDES (CO) 2022-03-24 WO disclosed
US-10016394-B2 PPARG modulators for treatment of osteoporosis THE SCRIPPS RESEARCH INSTITUTE (US) 2018-07-10 US disclosed
US-9982015-B2 Cyclin based inhibitors of CDK2 and CDK4 UNIVERSITY OF SOUTH CAROLINA (US) 2018-05-29 US disclosed
US-20170218018-A1 CYCLIN BASED INHIBITORS OF CDK2 AND CDK4 NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-08-03 US disclosed
US-20170035730-A1 PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED 2017-02-09 US disclosed
US-9376465-B2 Cyclin based inhibitors of CDK2 and CDK4 UNIVERSITY OF SOUTH CAROLINA (US) 2016-06-28 US disclosed
US-20150011730-A1 Cyclin Based Inhibitors of CDK2 and CDK4 NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-01-08 US disclosed
US-20140296484-A1 Cyclin Based Inhibitors of CDK2 and CDK4 UNIVERSITY OF SOUTH CAROLINA (US) 2014-10-02 US disclosed
EP-2410842-A1 SANITIZER FORMULATIONS Arch Chemicals, Inc. (US) 2012-02-01 EP disclosed
WO-2010111155-A1 SANITIZER FORMULATIONS ARCH CHEMICALS, INC. (US) 2010-09-30 WO disclosed
US-7482359-B2 Androgen receptor modulators MERCK & CO., INC. (US) 2009-01-27 US disclosed
US-20050008607-A1 Composition containing a carbonyl amine L'OREAL (FR) 2005-01-13 US disclosed
EP-0711278-A1 2-(2-HYDROXYPHENYL)-5-(N-PHENYLMETHYL-AMINOMETHYL)-PYRROLES AS ANTIPSYCHOTIC AGENTS SMITHKLINE BEECHAM PLC (GB) 1996-05-15 EP disclosed
WO-1995004037-A1 2-(2-HYDROXYPHENYL)-5-(N-PHENYLMETHYL-AMINOMETHYL)-PYRROLES AS ANTIPSYCHOTIC AGENTS SMITHKLINE BEECHAM PLC (GB) 1995-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150011730-A1 Cyclin Based Inhibitors of CDK2 and CDK4 CDK4, CDK2, CDK8 LMNA 1848/4885TSHR 1652/4885KDM4E 4044/4885
US-20170035730-A1 PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS PPARG, PPARA, PPARD LMNA 2152/4885TSHR 98/4885KDM4E 1844/4885
US-20050008607-A1 Composition containing a carbonyl amine CUTA, COL14A1, MAOA LMNA 352/4885TSHR 4069/4885KDM4E 237/4885
US-10016394-B2 PPARG modulators for treatment of osteoporosis PPARG, PPARA, PPARD LMNA 2152/4885TSHR 98/4885KDM4E 1844/4885
US-20170218018-A1 CYCLIN BASED INHIBITORS OF CDK2 AND CDK4 CDK4, CDK2, CDK8 LMNA 1848/4885TSHR 1652/4885KDM4E 4044/4885
US-20140296484-A1 Cyclin Based Inhibitors of CDK2 and CDK4 CDK4, CDK2, CDK8 LMNA 1848/4885TSHR 1652/4885KDM4E 4044/4885
US-20230159475-A1 COMPOUNDS WITH IMMUNOMODULATORY ACTIVITY AND THERAPEUTIC USES THEREOF CD47, CD74, ICOS LMNA 4810/4885TSHR 3657/4885KDM4E 2611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.